Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies

A CD24, immune-related technology, applied in the direction of immunoglobulin, chemical instruments and methods, pharmaceutical formulations, etc.
CN110799206APending Publication Date: 2020-02-14ONCOIMMUNE INC +1
7 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ONCOIMMUNE INC
Publication Date
2020-02-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism,Sjogren's syndrome, or type I diabetes. The CD24 protein may comprise a mature human CD24 or a variant thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] field of invention

[0002] The present invention relates to the use of CD24 protein in the treatment of immune-related adverse events (irAE) associated with cancer immunotherapy.

[0003] Background of the invention

[0004] The immune system has the ability to recognize and eliminate cancer in experimental model systems as well as in patients. As a result, cancer immunotherapy is emerging as one of the most promising areas of cancer treatment. Active cancer immunotherapy involves agents that amplify the natural immune response (including antibodies against PD-1, PD-L1, or CTLA-4); small molecules that modulate the tumor microenvironment; or the use of ex vivo stimulated tumor-infiltrating lymphocytes (TIL ), activated natural killer (NK) cells, or genetically engineered T cells (chimeric antigen receptor [CAR] and T cell receptor [TCR] modified T cells) for adoptive cell transplantation (ACT). In addition, other cancer immunotherapies that directly target the tumor c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More